Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., has received the drug registration certificate for Baclofen tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option for muscle spasms associated with multiple sclerosis [1]. Group 1 - The drug Baclofen is indicated for severe but reversible muscle spasms caused by multiple sclerosis [1]. - The medication may also show efficacy for spasms resulting from infectious, degenerative, traumatic, tumor-related, or unexplained spinal cord diseases [1].

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Baclofen tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option for muscle spasms associated with multiple sclerosis [1] Group 1 - The drug Baclofen is indicated for severe but reversible muscle spasms caused by multiple sclerosis [1] - Baclofen may also have certain efficacy for spasms resulting from infectious, degenerative, traumatic, tumor-related, or unexplained spinal cord diseases [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Baclofen tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new treatment option for muscle spasms associated with multiple sclerosis [1] Group 1 - The drug Baclofen is indicated for severe but reversible muscle spasms caused by multiple sclerosis [1] - Baclofen may also have certain efficacy for spasms resulting from infectious, degenerative, traumatic, tumor-related, or unexplained spinal cord diseases [1]